國家衛生研究院 NHRI:Item 3990099045/15089
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 908994      Online Users : 974
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/15089


    Title: Extremely low dose of erythropoiesis-stimulating agent may be associated with increased mortality in hemodialysis patients
    Authors: Yang, CW;Lin, MC;Shu, KH;Tung, KT;Tsai, WC;Yang, JY;Pai, MF;Wu, HY;Chiu, YL;Peng, YS;Hsu, SP;Wang, SH;Pan, SY
    Contributors: National Center for Geriatrics and Welfare Research
    Abstract: Introduction: Although high-dose erythropoiesis-stimulating agent (ESA) has been shown to increase mortality risk and adverse cardiovascular events in hemodialysis patients, the safety of extremely low-dose ESA is unclear. Methods: We retrospectively analyzed the association between ESA dose and mortality in the monthly dosing range of 0-43,000 U of equivalent epoetin alfa in 304 Taiwan hemodialysis patients by using Cox proportional hazard model and cubic spline model. Results: Compared with mean monthly ESA dose of 15,000-25,000 U (mean +/- standard deviation 20,609 +/- 2,662 U), monthly ESA dose of less than 15,000 U (mean +/- standard deviation 7,413 +/- 4,510 U) is associated with increased mortality. Monthly ESA dose of 25,001-43,000 U (mean +/- standard deviation 31,160 +/- 4,304 U) is not associated with higher mortality risk than monthly ESA dose of 15,000-25,000 U. The results were consistent in Cox proportional hazard models and cubic spline models. Subgroup analyses showed no significant heterogeneities among prespecified subgroups. Conclusions: Extremely low dose of ESA in hemodialysis patients may be associated with increased mortality risk. Future studies are warranted to prove this association.
    Date: 2023-05-23
    Relation: American Journal of Nephrology. 2023 May 23;54(1-2):25-34.
    Link to: http://dx.doi.org/10.1159/000529806
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0250-8095&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:001007914100003
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85160874245
    Appears in Collections:[Shi-Heng Wang] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    ISI001007914100003.pdf359KbAdobe PDF90View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback